Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 11, 2021

SELL
$18.04 - $22.09 $480,423 - $588,278
-26,631 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$16.59 - $33.89 $107,702 - $220,013
6,492 Added 32.24%
26,631 $803,000
Q4 2020

Feb 16, 2021

BUY
$27.5 - $37.92 $67,732 - $93,396
2,463 Added 13.93%
20,139 $871,000
Q3 2020

Nov 10, 2020

SELL
$34.44 - $43.75 $461,495 - $586,250
-13,400 Reduced 43.12%
17,676 $954,000
Q2 2020

Aug 13, 2020

BUY
$27.12 - $45.97 $126,921 - $215,139
4,680 Added 17.73%
31,076 $1.9 Million
Q1 2020

May 15, 2020

SELL
$26.16 - $63.5 $222,360 - $539,750
-8,500 Reduced 24.36%
26,396 $1.21 Million
Q4 2019

Feb 11, 2020

BUY
$46.96 - $61.67 $1,878 - $2,466
40 Added 0.11%
34,896 $3.06 Million
Q3 2019

Nov 07, 2019

SELL
$59.47 - $93.1 $225,986 - $353,780
-3,800 Reduced 9.83%
34,856 $3.2 Million
Q2 2019

Aug 01, 2019

SELL
$75.84 - $105.21 $334,681 - $464,291
-4,413 Reduced 10.25%
38,656 $4.92 Million
Q1 2019

May 08, 2019

BUY
$64.44 - $104.11 $262,786 - $424,560
4,078 Added 10.46%
43,069 $6.78 Million
Q4 2018

Feb 01, 2019

SELL
$59.1 - $93.26 $714,282 - $1.13 Million
-12,086 Reduced 23.66%
38,991 $3.87 Million
Q3 2018

Nov 01, 2018

BUY
$88.86 - $117.49 $16,972 - $22,440
191 Added 0.38%
51,077 $7.46 Million
Q2 2018

Jul 31, 2018

BUY
$99.64 - $127.59 $368,668 - $472,083
3,700 Added 7.84%
50,886 $7.99 Million
Q1 2018

May 11, 2018

BUY
$105.8 - $150.94 $327,980 - $467,914
3,100 Added 7.03%
47,186 $8.06 Million
Q4 2017

Feb 02, 2018

BUY
$81.25 - $130.7 $178,587 - $287,278
2,198 Added 5.25%
44,086 $7.85 Million
Q3 2017

Nov 09, 2017

BUY
$57.74 - $91.42 $2.42 Million - $3.83 Million
41,888
41,888 $5.75 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $29.3M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Td Asset Management Inc Portfolio

Follow Td Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Td Asset Management Inc with notifications on news.